ASCO22: 40% of Black patients with metastatic breast cancer are not informed about clinical trials

Black participation in clinical trials has been historically low compared to the rest of the population, limiting their opportunity to access new treatments. Recent research that will be presented at the 2022 ASCO Annual Meeting (3–6 June, Chicago, IL, USA) has investigated why Black patients with metastatic breast cancer do not enroll in clinical trials at rates equal to non-Black patients. The study consisted of a survey of 424 patients with metastatic breast cancer and is part of the BECOME (Black Experience of Clinical Trial and Opportunities for Meaningful Engagement) initiative. A total of 102 of the participants self-identified as...